Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 2Recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 9Other hematologic neoplasm 3

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Burkitt Lymphoma 4Recurrence 3Lymphoma, Large B-Cell, Diffuse 3Leukemia 3Neoplasm, Residual 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Biphenotypic, Acute 1

Interventions

Cyclophosphamide 72Cytarabine 61fludarabine phosphate 48venetoclax 42Peripheral Blood Stem Cell Transplantation 37fludarabine 34Busulfan 31Methotrexate 29Cyclosporine 29Mycophenolic Acid 28Filgrastim 27Azacitidine 27Antilymphocyte Serum 26Whole-Body Irradiation 22Etoposide 21Radiotherapy 20Melphalan 20Tacrolimus 19Rituximab 19Dexamethasone 16Methylprednisolone 15Granulocyte Colony-Stimulating Factor 15Decitabine 15Vincristine 14Cord Blood Stem Cell Transplantation 14Doxorubicin 13Clofarabine 11Mitoxantrone 10ibrutinib 9blinatumomab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recurrence × tisagenlecleucel × Other hematologic neoplasm × Clear all
NCT04094311 2026-04-20

Study of Out of Specification for Tisagenlecleucel

Novartis

Phase 3 Recruiting
200 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03123939 2021-07-21

Phase III B in Acute Lymphoblastic Leukemia

Novartis

Phase 3 Completed
69 enrolled 26 charts
LymphoidOther hematologic neoplasm

Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02228096 2020-11-23

ENSIGN

Novartis

Phase 2 Completed
75 enrolled 41 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡